bioRxiv Science⌕ Search

bioRxiv · 10.1101/2024.10.03.616555

Latexin facilitates neointimal formation via promoting smooth muscle cell proliferation and macrophage migration

Abstract

RationaleNeointimal formation is the major cause of cardiovascular diseases such as atherosclerosis and restenosis. Although restenosis rates are significantly reduced by the development of drug-eluting, the stent may not be implanted at all atherosclerotic sites, and long-term dual anti-platelet therapy is needed after stent implantation. Thus, it is essential to elucidate the detailed mechanisms underlying neointimal formation for developing novel therapies. Latexin (LXN), a previously identified pro-inflammatory protein, is highly expressed in vasculature and its expression is regulated by shear stress. Whether it plays a role in vascular remodeling, however, remains unknown. ObjectiveTo determine whether LXN is involved in neointimal formation, and if so, to define the molecular mechanisms involved. Methods and ResultsWe found that the expression of LXN was significantly increased in neointimal hyperplasia, as determined by western blot. Immunofluorescent staining indicated that increased LXN expression was predominantly localized in smooth muscle cells and macrophages. To determine the cell specific roles of LXN in neointimal formation after injury, we generated global, smooth muscle cell (SMC)-specific, endothelial specific-, and myeloid-specific LXN knockout (KO) mice. We found that global, SMC-, and myeloid-specific LXN deficiency markedly prevented neointimal hyperplasia in mice after carotid artery ligation, whereas LXN deficiency in endothelial cells had no effects. Mechanistically, we found that LXN deficiency in SMCs significantly attenuated SMC proliferation and migration, mainly through inhibiting the expression of platelet-derived growth factor (PDGF) receptors. Intriguely, LXN deficiency in macrophages inhibited monocyte chemoattractant protein-1 (MCP-1)-induced macrophage migration through inhibiting ERK phosphorylation. ConclusionsIn summary, we for the first time demonstrated that LXN is essentially involved in SMC proliferation and microphage migration. Specific inhibition of LXN signaling may provide a novel therapeutic strategy for the treatment of cardiovascular diseases, such as restenosis and atherosclerosis. Novelty and SignificanceO_ST_ABSWhat is known?C_ST_ABSO_LILatexin (LXN) is considered to be a novel pro-inflammatory protein and its expression is responsive to laminar shear stress. C_LIO_LIVascular inflammation, SMC proliferation, and macrophage migration are critical events in neointimal hyperplasia. C_LI What new information does this article contribute?O_LILXN is elevated in carotid artery ligation-induced neointimal hyperplasia in mice. C_LIO_LISMC-specific LXN deficiency prevents neointimal hyperplasia through inhibiting SMC proliferation migration via attenuating platelet-derived growth factor receptor expression. C_LIO_LIMyeloid-specific LXN deficiency prevents neointimal hyperplasia through inhibiting monocyte chemoattractant protein-1-induced macrophage migration and extracellular signal-regulated kinase phosphorylation. C_LI Neointimal formation is the major cause of cardiovascular disease such as atherosclerosis and restenosis after stenting or balloon angioplasty. Because of the development of drug-eluting stents, restenosis rates have been significantly reduced; however, it is still essential to explore the detailed mechanisms underlying neointimal hyperplasia. Latexin (LXN) is considered a novel pro-inflammatory protein that is ubiquitously expressed in vascular and immune cells. We found that LXN is elevated in neointimal hyperplasia, and its deficiency in SMCs and macrophages, but not in ECs, markedly prevents neointimal formation after carotid artery ligation in mice. Mechanistically, LXN deficiency in SMCs prevents SMC proliferation and migration via attenuation of platelet-derived growth factor receptor expression. Further, myeloid-specific LXN deficiency inhibits monocyte chemoattractant protein-1-induced macrophage migration via attenuation of extracellular signal-regulated kinase phosphorylation. For the first time, the present study demonstrated that LXN is a crucial mediator implicated in SMC biology and macrophage migration.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Kazama, K., Liu, W., Guo, Z.-F., Zhang, X., Zhang, C., Summer, R., Sun, J.. 2024-10-04. Latexin facilitates neointimal formation via promoting smooth muscle cell proliferation and macrophage migration. https://doi.org/10.1101/2024.10.03.616555

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

28S-rsRNA facilitates PASMC proliferation through PKM2 β-hydroxybutyrylation

Ribosomal RNA-derived small RNAs (rsRNAs) are nucleic acid fragments originating from rRNA, the functions and roles of which in diseases remain incompletely understood. We identified 28S rsRNA-CTC_L20, an rsRNA whose expression is upregulated in hypoxic pulmonary artery smooth muscle cells (PASMCs) and in lung tissues of pulmonary hypertension (PH) models. In hypoxic cells, 28S rsRNA-CTC_L20 promotes PASMC proliferation, and its knockdown mitigates SuHx-induced pulmonary hypertension and vascular remodeling. Mechanistically, 28S rsRNA-CTC_L20 modulates {beta}-hydroxybutyrate (BHB) production by maintaining the stability of ketogenic enzyme mRNAs through its "CTGNNGG" motif. Elevated levels of BHB enhance the {beta}-hydroxybutyrylation modification at K166 of pyruvate kinase M2 (PKM2), increasing its activity and driving glycolysis to sustain proliferation. These results link ketone body metabolism to glycolysis in hypoxic cells and define an rsRNA-BHB-PKM2 {beta}-hydroxybutyrylation axis in PH. They also point to 28S rsRNA-CTC_L20 as a potential target for treating vascular remodeling.

physiology↗

Selective activation of estrogen receptors modulates electrical activity and insulin secretion in human EndoC-βH1 cells

Estrogen receptors (ERs), ER and ER{beta} have important roles in the physiology of the endocrine pancreas in animal models, but the effects of ER activation on insulin-secreting human cells are still poorly understood. Here, we investigated the role of ER and ER{beta} as modulators of electrical activity and insulin secretion in the insulin-secreting human cell line EndoC-{beta}H1. Immunocytochemical analysis revealed a widespread cellular distribution of ER, while ER{beta} was predominantly localized outside the nucleus. We observed that both estradiol (E2) and the ER{beta} agonist diarylpropionitrile (DPN) led to a decrease in insulin secretion in the absence of stimulatory glucose concentrations, without affecting insulin content. Patch-clamp experiments revealed that a 48-hour treatment with either the ER agonist PPT or DPN resulted in depolarization of the resting membrane potential, increased action potential firing frequency, and altered the action potential waveform in EndoC-{beta}H1 cells. PPT increased voltage-dependent Ca2+ channel currents, while DPN reduced K+ and Na+ currents. These results suggest that activation of ER and ER{beta} modulates beta-cell electrical activity through distinct pathways involving ion channels. The effects of E2, PPT, and DPN were not caused by altered expression levels of ion channel genes after 48 hours of treatment. This suggests that these receptors act extranuclearly without affecting gene expression. Together, our findings demonstrate that selective activation of ER and ER{beta} modulates beta-cell excitability through distinct electrophysiological mechanisms and that E2 and DPN reduce basal insulin secretion in human EndoC-{beta}H1 cells. These results support ER and ER{beta} as potential targets for modulating human pancreatic beta-cell function.

physiology↗

Body weight modifies the efficacy of lifespan-extending interventions in ad libitum-fed mice

Geroprotective interventions are often assessed by extension of lifespan in ad libitum-fed mice. Increased lifespan could therefore reflect rescue of adverse phenotypes of unhealthy controls. We analysed body weight and survival for 33,780 mice in the Interventions Testing Program (ITP) to test whether treatment effects varied with body weight. In males, each added standard deviation of attained adult weight made treatment 6% more favourable (HR 0.94), more apparent for interventions that lowered body weight (HR 0.90). Median lifespan increase rose from 6.2% in mice in the lightest quartile to 20.2% in the heaviest pre-dosing weight quartile among those experiments, mainly because control survival declined more steeply with weight than that of the intervention group. The effect of body weight was consistent across 13 of 14 compounds and reflected weight attained during adulthood rather than in early life. Weight-dependence of intervention effects was weak in ITP females, possibly because median survival of controls exceeded that of every sampled non-ITP female control group. Amelioration of weight-associated risk is therefore implicated as a major contributor to lifespan increases relative to heavy, short-lived controls. The geroprotective effects of these interventions may thus be less apparent in metabolically healthier mice or humans.

physiology↗